Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | VDR | P11473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4641154 | 0.93 | CYP2D6 (0.51) | CYP2D6CYP1A2GAAKMT2ASMN1; SMN2 | |
| SCHEMBL10633561 | 0.93 | CYP2D6 (0.51) | CYP2D6CYP1A2GAAKMT2ASMN1; SMN2 | |
| SCHEMBL506784 | 0.87 | CYP2D6 (0.52) | CYP2D6CYP1A2GAAKMT2ASMN1; SMN2 | |
| SCHEMBL507364 | 0.87 | CYP2D6 (0.52) | CYP2D6CYP1A2GAAKMT2ASMN1; SMN2 | |
| SCHEMBL181292 | 0.87 | CYP2D6 (0.52) | CYP2D6CYP1A2GAAKMT2ASMN1; SMN2 | |
| SCHEMBL25859829 | 0.84 | CYP2D6 (0.50) | CYP2D6CYP1A2KMT2ASMN1; SMN2CYP3A4 | |
| SCHEMBL21488522 | 0.84 | CYP2D6 (0.50) | CYP2D6CYP1A2KMT2ASMN1; SMN2CYP3A4 | |
| SCHEMBL13998567 | 0.83 | CYP2D6 (0.52) | CYP2D6CYP1A2GAAKMT2ASMN1; SMN2 | |
| SCHEMBL15506544 | 0.83 | CYP2D6 (0.49) | CYP2D6CYP1A2GAAKMT2ASMN1; SMN2 | |
| SCHEMBL14780313 | 0.83 | CYP2D6 (0.58) | CYP2D6CYP1A2GAAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 500 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230006252-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FUNCTIONALIZED LINEAR SULFONATE ESTER DERIVATIVE COMPOUND CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2023-01-05 | — | — | US | claimed |
| US-20200388879-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FUNCTIONALIZED LINEAR SULFONATE ESTER DERIVATIVE COMPOUND CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-12-10 | — | — | US | claimed |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | GLENMARK SPECIALITY S.A. (CH) | 2026-03-17 | — | — | US | disclosed |
| EP-4034535-B1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| US-12565497-B2 | Sulfone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4698520-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | Gandeeva Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20260049092-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4692090-A1 | TRICYCLIC COMPOUND AS ATR KINASE INHIBITOR | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-12544374-B2 | AZA-quinoline compounds and uses thereof | NOVARTIS AG (CH) | 2026-02-10 | — | — | US | disclosed |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-7214681-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
| WO-2006012577-A2 | QUINAZOLINONE DERIVATIVES USEFUL FOR THE REGULATION OF GLUCOSE HOMEOSTASIS AND FOOD INTAKE | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1594867-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | OSI PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004072031-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200388879-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FUNCTIONALIZED LINEAR SULFONATE ESTER DERIVATIVE COMPOUND CONTAINING ELECTROLYTE ADDITIVES | SELENOI, SELE, SORD | CYP2D6 4469/4885CYP1A2 4463/4885GAA 1158/4885 |
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | CYP2D6 1749/4885CYP1A2 1211/4885GAA 2805/4885 |
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | PTK2B, MAP3K10, MAP3K20 | CYP2D6 2556/4885CYP1A2 3111/4885GAA 4486/4885 |
| US-20260049092-A1 | ANTIBACTERIAL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, FPR1 | CYP2D6 847/4885CYP1A2 2041/4885GAA 3838/4885 |
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, SUZ12, NR3C1 | CYP2D6 2158/4885CYP1A2 1442/4885GAA 3515/4885 |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | GPR119, IAPP, SLC5A1 | CYP2D6 615/4885CYP1A2 446/4885GAA 107/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | CYP2D6 1521/4885CYP1A2 1753/4885GAA 2125/4885 |
| US-12544374-B2 | AZA-quinoline compounds and uses thereof | EZH2, NR3C1, SUZ12 | CYP2D6 1965/4885CYP1A2 944/4885GAA 3856/4885 |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | CYP2D6 1146/4885CYP1A2 3089/4885GAA 4403/4885 |
| US-12565497-B2 | Sulfone derivatives | CXCR1, CCR1, SULT1E1 | CYP2D6 113/4885CYP1A2 588/4885GAA 2525/4885 |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | IAPP, GPR119, SLC5A1 | CYP2D6 527/4885CYP1A2 515/4885GAA 91/4885 |
| US-20230006252-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FUNCTIONALIZED LINEAR SULFONATE ESTER DERIVATIVE COMPOUND CONTAINING ELECTROLYTE ADDITIVES | SELENOI, SELE, SORD | CYP2D6 4469/4885CYP1A2 4463/4885GAA 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.